Eli Lilly & Co. (LLY)

163.87
0.57 0.35
NYSE : Health Technology
Prev Close 163.30
Open 164.07
Day Low/High 162.37 / 164.77
52 Wk Low/High 101.36 / 167.43
Volume 1.96M
Avg Volume 3.77M
Exchange NYSE
Shares Outstanding 957.04M
Market Cap 156.28B
EPS 5.00
P/E Ratio 27.17
Div & Yield 2.96 (1.69%)

Latest News

Jim Cramer: We Have a Rip Snorting Rally Unfathomable 2 Months Ago

Jim Cramer: We Have a Rip Snorting Rally Unfathomable 2 Months Ago

So what's the narrative? Simple: the recession is ending, it turned out to be a V recession and recovery after all.

A Triangle Formation on Drug Maker Eli Lilly Is Ready for an Upside Breakout

A Triangle Formation on Drug Maker Eli Lilly Is Ready for an Upside Breakout

The question is whether you want to buy before the breakout or after the breakout?

This Chart Pattern Hints at a Bullish Future

This Chart Pattern Hints at a Bullish Future

The bullish reversal pattern is appearing not just in single names, but also in whole sectors.

I Like What Eli Lilly Is Doing, but Have All the Horses Left the Barn?

I Like What Eli Lilly Is Doing, but Have All the Horses Left the Barn?

Here are my thoughts on the quarter and trading the stock.

Employment Figures, Trading Thoughts, and 'Busting a Move'

Employment Figures, Trading Thoughts, and 'Busting a Move'

Watching first-time jobless claims and trading volume, plus some thoughts on defense names like Raytheon and Lockheed Martin, and tech names like Lam Research.

Eli Lilly Cut to Neutral at UBS

Eli Lilly Surges to a New High and a New Price Target Opens Up

Eli Lilly Surges to a New High and a New Price Target Opens Up

An inspiring performance.

You Can Gild the Lilly

You Can Gild the Lilly

Our technical strategy says that Eli Lilly can be bought on strength over $144, as the name looks more attractive along with others in the health care sector.

3 Strong Long-Term Buys for Uncertain Times

3 Strong Long-Term Buys for Uncertain Times

These pharmaceutical names have what it takes amid the current crisis and for the long run.

I Have More Hope for Eli Lilly's Research Partnership Than Its Charts

I Have More Hope for Eli Lilly's Research Partnership Than Its Charts

LLY is entering into a new partnership with AbCellera Biologics in an attempt to develop an antibody for Covid-19.

Jim Cramer: Do You Really Want to Sell Now?

Jim Cramer: Do You Really Want to Sell Now?

The answer to that question depends on several factors, so let's break them down.

The Fed's Moves, Trading 5 Stocks, Coronavirus and the Market: Market Recon

The Fed's Moves, Trading 5 Stocks, Coronavirus and the Market: Market Recon

It's no secret that the Fed would like to get out of the short-term repo business.

Adding to My Biotech Positions When Profit-Taking Hits

Adding to My Biotech Positions When Profit-Taking Hits

Here's my strategy which has worked particularly well.

All-Time Highs

It is nice to once again be sitting in for Doug Kass this Friday at the Daily Diary. I will be coming to you from a Starbucks in downtown Miami this morning, as the internet in my building has decided to opt for a three-day weekend. Oh, the perils o...

Biotech's Big Week Finds a Big Winner in Adaptimmune

Biotech's Big Week Finds a Big Winner in Adaptimmune

The clinical stage company sees its shares climb after announcing some significant news during this week's J.P. Morgan Healthcare Conference.

4 Favorite Biotech Stock Picks for 2020

4 Favorite Biotech Stock Picks for 2020

The Medical Technology Stock Letter's top pick rose 357% in 2019.

3 Powerhouse Pharma Stock Favorites

3 Powerhouse Pharma Stock Favorites

These healthcare stalwarts look attractive for growth and income.

Lilly Raised at Morgan Stanley

Eli Lilly Has the Base to Support a New Rally

Eli Lilly Has the Base to Support a New Rally

Shares of the pharmaceutical company received a quant upgrade Monday.

Jim Cramer: Nothing's Changed, Except the Prices

Jim Cramer: Nothing's Changed, Except the Prices

The market is throwing a Halloween sale right now that it doesn't need to throw, and that's an opportunity.

Jim Cramer: Drug Stocks Are Too Cheap

Jim Cramer: Drug Stocks Are Too Cheap

These stocks are priced for total imperfection. That's just what you want.

Jim Cramer: The Soundness of My Methods

Jim Cramer: The Soundness of My Methods

A little bit of luck and a lot of homework can go a long way to make Big Money out of Mad Money. It's buying a Biogen, a Centene, or a Bristol-Myers that could do just that for you.

6 Top Biopharmaceutical Stock Picks You Should Know About

6 Top Biopharmaceutical Stock Picks You Should Know About

The aging population is creating a massive tailwind for companies that provide cutting-edge health care.

Jim Cramer: How to Survive This Violent Rotation

Jim Cramer: How to Survive This Violent Rotation

Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.

A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks

A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks

Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.